AstraZeneca’s Bydureon fails to show cardio-protection

AstraZeneca’s Bydureon fails to show cardio-protection | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado

The only conference focused solely on the pharmaceutical development of peptide therapeutics.

AstraZeneca’s Bydureon fails to show cardio-protection

Peptide News from Biotech and Pharma, Raw News September 14, 2017

Results showed the once-weekly glucagon-like peptide-1 (GLP-1) agonist Bydureon did not increase the risk of a major adverse cardiovascular event ...